Related to Merck KGaA Nabs Threshold’s Late-Stage Hypoxia-Targeting Anticancer Drug for Initial $25M

• Arginetix Pockets $10.75M to Further R&D of Arginase Inhibitors
  
• Merck KGaA and Lonza Separately Acquire Indian Bioscience Companies
  
• Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis
  
• Preliminary Data on Genta’s Melanoma Drug Sends Firm Crashing
  
• Cell Proliferation and Immune Response Related Genes Could Predict Melanoma Survival Rate
  
• Investigators Say CRAF-BRAF Interaction May Explain Nexavar’s Failure in Melanoma
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Comprehensive Sequencing of Lung Cancer and Melanoma Genomes Catalogs 55,000 Mutations
  
• Pfizer to Re-Test Failed Melanoma Drug in Phase III with Debiopharm
  
• Merck KGaA to Dole Out $7.2B for Millipore
  
• Broad Institute to Use Genedata’s Small Molecule Screener
  
• Genentech Taps Graffinity’s Fragment-Based Drug Discovery Technology
  
• Novartis to Pay $45M Up Front in Cancer Collaboration with Array BioPharma
  
• Ariadne and Aureus to Marry Bioinformatics Expertise
  
• Scancell and ImmuneRegen to Evaluate Combination of Their Vaccine Technologies
  
• Ascenta Enters Deal Potentially Worth $398M with Sanofi-Aventis
  
• BMS’ Ipilimumab Proves Itself in Metastatic Melanoma Patients
  
• Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal
  
• Gilead Steps Into Kinase Biology with Acquisition of CGI Pharmaceuticals for up to $120M
  
• Vitae Earns $14M from Boehringer Ingelheim with Start of Phase I Development